Boston Scientific Estimates Net Sales Growth For The Full Year 2024 Of Approximately 8.5%-9.5% Y/Y On A Reported Basis, And Approximately 8%-9% On An Organic Basis. The Company Sees Adjusted Eps, Of $2.23-$2.27 Versus Consensus Of $2.24
Portfolio Pulse from Benzinga Newsdesk
Boston Scientific projects net sales growth of 8.5%-9.5% year-over-year on a reported basis and 8%-9% on an organic basis for the full year 2024. The company anticipates adjusted EPS to be between $2.23 and $2.27, aligning with the consensus estimate of $2.24.
January 31, 2024 | 11:43 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Boston Scientific expects higher sales growth and an adjusted EPS that meets market expectations for 2024, indicating a positive outlook for the company's financial performance.
The projected sales growth and EPS guidance provided by Boston Scientific are positive indicators of the company's future performance. Since the EPS guidance is in line with consensus estimates, it suggests that the company's financial health is as expected by analysts, which could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100